For example, a combinatorial therapy with MAPK-signaling inhibitors and histone-deacetylase inhibitors showed a synergistic effect in reexpressing the NIS gene and in recovering the radioiodine trapping in BRAFV600E thyroid-cancer cell lines (62). The gene discussed is SLC5A5; the disease is thyroid cancer.